Travoprost Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

It is formulated by 10 pharmaceutical companies such as CHARTWELL RX, NOVARTIS, APOTEX and others. It is marketed under 3 brand names, including TRAVOPROST, IZBA, IDOSE TR. Available in 3 different strengths, such as 0.004%, 0.003%, 75MCG, and administered through 2 routes including SOLUTION/DROPS;OPHTHALMIC, IMPLANT;INTRACAMERAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 10 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"70859","ingredient":"TRAVOPROST","trade_name":"TRAVATAN Z","family_id":"c7ae5cf814f44c11a348","publication_number":"US8323630B2","cleaned_patent_number":"8323630","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-09-20","publication_date":"2012-12-04","legal_status":"Granted"} US8323630B2 Formulation 04 Dec, 2012 Granted 20 Sep, 2027
{"application_id":"70866","ingredient":"TRAVOPROST","trade_name":"TRAVATAN Z","family_id":"640ac487b0204d64a80d","publication_number":"US8388941B2","cleaned_patent_number":"8388941","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-09-20","publication_date":"2013-03-05","legal_status":"Granted"} US8388941B2 Formulation 05 Mar, 2013 Granted 20 Sep, 2027
{"application_id":"70613","ingredient":"TRAVOPROST","trade_name":"IZBA","family_id":"62d0b47bd77a4d80b2e5","publication_number":"US9144561B2","cleaned_patent_number":"9144561","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2015-09-29","legal_status":"Granted"} US9144561B2 Formulation 29 Sep, 2015 Granted 13 Mar, 2029
{"application_id":"70612","ingredient":"TRAVOPROST","trade_name":"IZBA","family_id":"62d0b47bd77a4d80b2e5","publication_number":"US8754123B2","cleaned_patent_number":"8754123","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-05-19","publication_date":"2014-06-17","legal_status":"Granted"} US8754123B2 Formulation 17 Jun, 2014 Granted 19 May, 2029
{"application_id":"70579","ingredient":"TRAVOPROST","trade_name":"IZBA","family_id":"62d0b47bd77a4d80b2e5","publication_number":"US8722735B2","cleaned_patent_number":"8722735","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-10","publication_date":"2014-05-13","legal_status":"Granted"} US8722735B2 Formulation 13 May, 2014 Granted 10 Oct, 2029
{"application_id":"70611","ingredient":"TRAVOPROST","trade_name":"IZBA","family_id":"62d0b47bd77a4d80b2e5","publication_number":"US8178582B2","cleaned_patent_number":"8178582","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-10","publication_date":"2012-05-15","legal_status":"Granted"} US8178582B2 Formulation 15 May, 2012 Granted 10 Oct, 2029
{"application_id":"70837","ingredient":"TRAVOPROST","trade_name":"TRAVATAN Z","family_id":"c7ae5cf814f44c11a348","publication_number":"US8268299B2","cleaned_patent_number":"8268299","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-13","publication_date":"2012-09-18","legal_status":"Granted"} US8268299B2 Formulation 18 Sep, 2012 Granted 13 Oct, 2029
{"application_id":"164419","ingredient":"TRAVOPROST","trade_name":"IDOSE TR","family_id":"4e86e3eb6d7e47a68c41","publication_number":"US12201557B2","cleaned_patent_number":"12201557","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-06-18","publication_date":"2025-01-21","legal_status":"Granted"} US12201557B2 Molecular Formulation 21 Jan, 2025 Granted 18 Jun, 2030
{"application_id":"119671","ingredient":"TRAVOPROST","trade_name":"IDOSE TR","family_id":"4e86e3eb6d7e47a68c41","publication_number":"US10206813B2","cleaned_patent_number":"10206813","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-10-17","publication_date":"2019-02-19","legal_status":"Patented case"} US10206813B2 Formulation 19 Feb, 2019 Patented case 17 Oct, 2030
{"application_id":"119629","ingredient":"TRAVOPROST","trade_name":"IDOSE TR","family_id":"4e86e3eb6d7e47a68c41","publication_number":"US11426306B2","cleaned_patent_number":"11426306","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-10-17","publication_date":"2022-08-30","legal_status":"Granted"} US11426306B2 Formulation 30 Aug, 2022 Granted 17 Oct, 2030
{"application_id":"164420","ingredient":"TRAVOPROST","trade_name":"IDOSE TR","family_id":"4e86e3eb6d7e47a68c41","publication_number":"US12201555B2","cleaned_patent_number":"12201555","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-02-14","publication_date":"2025-01-21","legal_status":"Granted"} US12201555B2 Molecular Formulation 21 Jan, 2025 Granted 14 Feb, 2031

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Travoprost

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.